Found 511 clinical trials
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19.
STUDY DIRECTED AT HOUSEHOLD MEMBERS WITH A COVID POSITIVE CASE AT HOME.
- 198 views
- 23 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2.
STUDY WITH IV ANTIBODY COCKTAIL TO TREAT PATIENTS WITH COVID MILD TO MODERATE DIAGNOSED BY PCR ( SWAB)
- 208 views
- 13 Aug, 2020
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease.
We are currently recruiting participants for a clinical research study to evaluate the efficacy of an investigational medication in adults with Diabetic Kidney Disease.
- 12 views
- 14 Jan, 2021
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
Hepatology (Liver, Pancreatic, Gall Bladder)
-
Currently Recruiting
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and MET. NIVO/IPI are monoclonal antibodies (mAbs) that inhibit the immune checkpoint proteins programmed death receptor-1 (PD-1
- 27 views
- 15 Sep, 2020
- 1 location
-
Phase 4 trial
-
Accepting adults
-
Currently Recruiting
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
- 74 views
- 08 Nov, 2020
- 1 location
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
A Phase I, dose-escalation study investigating the safety and tolerability of intratumoral injection of an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) in patients with cancer
The purpose of this study is to test the safety and tolerability of a new drug called 2141-V11 in participants who have skin lesions associated with their cancer. It will also test how the body processes the drug and whether 2141-V11 has cancer fighting activity in humans. The study drug …
- 43 views
- 23 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Combination Chemotherapy With or Without Filgrastim Before Surgery High-Dose Chemotherapy and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining isotretinoin and monoclonal antibodies may kill
- 46 views
- 07 Nov, 2020
- 15 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Gastroenterology
-
Currently Recruiting
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
- 7 views
- 07 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Gastroenterology
-
Currently Recruiting
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the
- 129 views
- 07 Nov, 2020
- 12 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Oncology
-
Currently Recruiting
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such
- 33 views
- 07 Nov, 2020
- 1 location